CN113116973A - Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof - Google Patents

Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof Download PDF

Info

Publication number
CN113116973A
CN113116973A CN202110491885.XA CN202110491885A CN113116973A CN 113116973 A CN113116973 A CN 113116973A CN 202110491885 A CN202110491885 A CN 202110491885A CN 113116973 A CN113116973 A CN 113116973A
Authority
CN
China
Prior art keywords
group
traditional chinese
paeony
mice
chinese medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110491885.XA
Other languages
Chinese (zh)
Other versions
CN113116973B (en
Inventor
郝静超
赵荣惠
文凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kunming Medical University
Original Assignee
Kunming Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kunming Medical University filed Critical Kunming Medical University
Priority to CN202110491885.XA priority Critical patent/CN113116973B/en
Publication of CN113116973A publication Critical patent/CN113116973A/en
Application granted granted Critical
Publication of CN113116973B publication Critical patent/CN113116973B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536Prunella or Brunella (selfheal)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287Chrysanthemum, e.g. daisy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/35Caprifoliaceae (Honeysuckle family)
    • A61K36/355Lonicera (honeysuckle)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • A61K36/748Oldenlandia or Hedyotis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a novel traditional Chinese medicine compound for preventing and treating sicca syndrome and a preparation method thereof, which are characterized in that Chinese herbal medicine components are reasonably matched, and the effective components of the formula comprise common selfheal fruit-spike, desmodium, spreading hedyotis herb, chrysanthemum and honeysuckle which are all Chinese herbal medicine components. The method comprises the following processes and steps: decocting Prunellae Spica, herba Lysimachiae Christinae, herba Hedyotidis Diffusae, flos Chrysanthemi, and flos Lonicerae with 5 times and 3 times of distilled water for 1 hr each time, mixing decoctions, and concentrating under reduced pressure. Animal experiment screening proves that the obtained concentrated solution has good effects of improving xerophthalmia, improving gland functions, reducing autoantibody level and resisting inflammation. The maximum dosage experiment proves that the concentrated solution has higher clinical safety. Can be used for preventing and treating xerosis syndrome mainly caused by dry eye, lymphocyte invasion of secretory gland, and inflammation, and has no recurrence.

Description

Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof
Technical Field
The invention relates to a medical application of a traditional Chinese medicine compound for preventing and treating sicca syndrome, in particular to an application of the compound in treating the sicca syndrome.
Background
Sicca syndrome (A)
Figure BDA0003052680130000011
SS) is also known as sjogren's syndrome and is a chronic inflammatory autoimmune disease that involves primarily the exocrine glands. It is divided into primary and secondary categories. The typical clinical manifestations are that salivary gland and lacrimal gland are damaged, the function is reduced, and the symptoms of dry mouth and eyes are caused, and other exocrine glands and other organs outside gland body are involved to cause multi-system damage. There are a number of autoantibodies and hyperimmune globulin in the patient's serum. Sjogren syndrome occurs well after menopause or in women between 30 and 40 years of age, with a prevalence of about 0.3-0.4% and up to 0.77% in the elderly population.
No radical cure method is available for the disease at present. In clinic, measures are mainly taken for improving symptoms, controlling and delaying the progress of tissue and organ damage caused by immune response and secondary infection. The treatment aims to relieve dry mouth and dry eyes. The western medicine clinical treatment mainly comprises substitution therapy and symptomatic treatment, wherein the substitution therapy adopts 'artificial tears', 'saliva substitute' and the like as local treatment medicines for improving dry eyes and dry mouths. And symptomatic treatment such as systemic treatment with hydroxychloroquine sulfate, glucocorticoid, and immunosuppressant (such as cyclophosphamide). The use of biologics such as B lymphocyte monoclonal antibodies (e.g., CD20 and CD22 monoclonal antibodies) to increase residual salivary gland function stabilizes Ig G levels. Other approaches such as muscarinic agonists, stem cell therapies, etc. have also been investigated. But all are difficult to cure radically and easy to repeat.
Under the guidance of the holistic view and syndrome differentiation theory of traditional Chinese medicine, the traditional Chinese medicine has certain effect on preventing and treating sicca syndrome. Total glucosides of paeony is a classic and effective Chinese patent medicine for treating sicca syndrome at present, is an immunomodulator, and can adjust over-high or over-low immunity of a patient to a normal level. But when used alone, the traditional Chinese medicine composition has slow effect, can not quickly improve the dry mouth and eyes symptom, and can not quickly reduce the infiltration degree of gland lymphocytes and reduce the expression quantity of autoantibodies. In patent 201210296796.0, although the compound of Chinese herbal medicine using white peony root as one of the main Chinese herbal medicines has been shown to effectively inhibit rheumatoid factor and antibody index, it has not good intervention effect on lymphocyte infiltration, autoantibody SSA, SSB, ANA, inflammation TNF- α, BAFFR factor, etc. in gland with xerosis specificity. In addition, some Chinese herbal compound medicines are applied to the treatment of the sjogren syndrome, such as patents 201210345391.1 and 201610918771.8, but the Chinese herbal compound medicines have the defects of more traditional Chinese medicines, more complex formula and preparation process, more dosage of single-day medicine and the like.
Disclosure of Invention
In view of the above situation, the present invention aims to provide an application of a traditional Chinese medicine compound for preventing and treating xerophthalmia, xerostomia, secretory gland function improvement and autoantibody level reduction and inflammation.
The invention relates to a traditional Chinese medicine compound, which is characterized in that the main active ingredients of the traditional Chinese medicine compound comprise common selfheal fruit-spike, desmodium, oldenlandia diffusa, chrysanthemum and honeysuckle.
The traditional Chinese medicine compound is characterized in that the main active ingredients comprise 2g-30g of selfheal, 2g-30g of desmodium, 2g-30g of oldenlandia diffusa, 2g-30g of chrysanthemum and 2g-30g of honeysuckle.
The preparation method of the traditional Chinese medicine compound is characterized by comprising the following steps of decocting, concentrating and mixing 2g-30g of selfheal, 2g-30g of desmodium, 2g-30g of oldenlandia diffusa, 2g-30g of chrysanthemum and 2g-30g of honeysuckle with water to obtain a finished product.
The Chinese herbal compound is a medicine for preventing or treating sjogren syndrome and a preparation method and application thereof.
The specific description is as follows:
the technical scheme for solving the problem is that the traditional Chinese medicine compound and the preparation method thereof are characterized by comprising the following steps:
the traditional Chinese medicine compound composition for treating sicca syndrome comprises the following raw material medicines: prunellae Spica, herba Lysimachiae Christinae, herba Hedyotidis Diffusae, flos Chrysanthemi and flos Lonicerae.
The traditional Chinese medicine compound composition for treating sicca syndrome comprises the following raw material medicines in parts by weight: 2g to 30g of selfheal, 2g to 30g of desmodium, 2g to 30g of spreading hedyotis herb, 2g to 30g of chrysanthemum and 2g to 30g of honeysuckle.
The traditional Chinese medicine compound composition for treating sicca syndrome is any one of dosage forms in pharmaceutics. The Chinese medicinal composition can be directly or indirectly added with pharmaceutically acceptable excipient to make into any dosage form in pharmacy.
Preferably, the dosage form is decoction, powder, pill, paste, tablet or effervescent tablet.
The preparation is prepared by a conventional process, such as:
the decoction is as follows: mixing the Chinese herbal pieces, soaking in 500mL water, decocting, filtering, mixing filtrates, concentrating to 100mL, and making into liquid. The raw materials are soaked for 20-30 minutes before being decocted generally, the medicines are decocted with normal water quality, each dose of the medicines is decocted for 2 times, 500mL is added for each time, and after the medicines are decocted, the filtrates are combined and concentrated.
The powder is as follows: pulverizing the raw materials, mixing, and making into powder.
The pill preparation comprises the following steps: the compound spherical or spheroidal solid dosage form is prepared by adding the raw material powder or the raw material extract into any available adhesive or other auxiliary materials.
The paste is prepared by the following steps: decocting the raw materials in the compound with water or vegetable oil, filtering, and making into dosage form.
The tablet comprises the following components: pulverizing the raw materials, mixing, adding any binder or other adjuvants, and making into desired dosage form.
The effervescent tablet comprises: pulverizing the raw materials, mixing, adding binder or other adjuvants, effervescent disintegrant, and correctant, and making into desired dosage form.
The Chinese medicinal compound composition for treating sicca syndrome can also be prepared into teabags. And (3) subpackaging the coarse powder of the traditional Chinese medicine decoction pieces or part of the small pieces of the traditional Chinese medicine decoction pieces in the compound into cotton gauze tea bags or diamond tea bags according to the formula compatibility weight ratio. The tea bag is soaked in 100mL of boiled water at 60-100 ℃ for 10-15 minutes, and then can be drunk.
The pharmacological effects of the invention are as follows:
the formula of the invention selects the selfheal, the desmodium, the oldenlandia diffusa, the chrysanthemum and the honeysuckle, and is obtained by combining the traditional Chinese medicine theory and the modern pharmacology and repeatedly carrying out clinical verification. The effects of the traditional Chinese medicines are as follows:
spica Prunellae, pungent, bitter and cold in nature, can clear heat and purge fire, improve vision, dissipate nodulation and relieve swelling. Is used for treating goiter and lymphadenectasis, and also has antioxidant, antitumor, antiviral and immunity regulating effects;
oldenlandia diffusa, bitter, sweet, cold in flavor and non-toxic. Clear heat and remove toxicity, cure abscess and remove dampness. Has antitumor, antibacterial, antiinflammatory, fibroblast proliferation inhibiting, immunity regulating, and nervous system protecting effects. For cough and asthma due to lung heat, tonsillitis, pharyngolaryngitis, venomous snake bite, etc., it is combined with jin Yin Hua to treat sore, furuncle, pyogenic infections, etc.
Honeysuckle flower, flos Lonicerae, with warm nature, bitter and sweet taste, is nontoxic. It enters lung and stomach meridians. Clearing away heat and toxic material, diminishing inflammation and relieving swelling. It can be used for treating fever due to affection of exogenous wind-heat or epidemic febrile disease, heatstroke, toxic heat, dysentery, carbuncle, furuncle, pharyngitis, and various infectious diseases. The extract has strong antiinflammatory, antibacterial and antipyretic effects.
Jin Qian Cao is slightly cold in nature, sweet and salty in flavor. It enters liver, gallbladder, kidney and bladder meridians. Has effects in clearing away heat and dampness, relieving stranguria, relieving swelling, promoting diuresis, and eliminating jaundice. Has anti-inflammatory effect; has inhibitory effect on cellular immunity and humoral immunity; relaxing smooth muscle of blood vessel, and inhibiting platelet aggregation. The decoction and granule have antibacterial and antiinflammatory effects and are effective in inhibiting Staphylococcus aureus.
Chrysanthemum, slightly cold in nature, bitter and sweet in taste. It enters lung and liver meridians. Dispel wind and clear heat, pacify liver and improve vision, clear heat and remove toxicity. Can be used for treating wind-heat type common cold, headache, giddiness, conjunctival congestion, swelling and pain, dim eyesight, sore, carbuncle, and toxic swelling.
The compatibility of the selfheal, the oldenlandia diffusa and the honeysuckle in the composition enhances the effects of the prescription on improving xerophthalmia, improving gland functions, reducing autoantibody level and resisting inflammation.
Has the advantages that:
1. the main active ingredients in the traditional Chinese medicine compound comprise common selfheal fruit-spike, desmodium, spreading hedyotis herb, chrysanthemum and honeysuckle. In the formula, the selfheal is taken as a monarch drug and plays a role in treating main diseases; the oldenlandia diffusa is used as a ministerial drug to assist the main drug to play a role; the honeysuckle, the desmodium and the chrysanthemum are all adjuvant drugs, treat the accompanying diseases and simultaneously eliminate the possible toxicity of monarch drugs and ministerial drugs; the herba Lysimachiae Christinae also serves as guiding drug, and has effects of guiding meridian downward and harmonizing Chinese medicinal compound properties.
The compound Chinese medicine of the invention has the functions of obviously enhancing the treatment of stagnation and detumescence, resisting inflammation and detoxifying and regulating immunity by matching the selfheal with the oldenlandia diffusa. The 2 medicines have common property in performance and efficacy, mainly take the selfheal as the main component, take the oldenlandia diffusa as the auxiliary component, and can improve the effect and the curative effect of the selfheal.
The inventor finds that the Chinese herbal compound has good effect under the condition that the dosage of the selfheal and the spreading hedyotis herb is about 1:1, the proportion of other medicines can be changed, the influence on the drug effect is small, and the compound plays a synergistic effect.
In conclusion, the invention conforms to the compatibility principle of the traditional Chinese medicines and has no incompatibility. No diet contraindication.
2. The traditional Chinese medicine used in the traditional Chinese medicine compound is common traditional Chinese medicine and has simple formula. It has small dosage and definite effect on preventing and treating sjogren's syndrome. Animal experiment screening proves that the obtained concentrated solution has good effects of improving xerophthalmia, improving gland functions, reducing autoantibody level and resisting inflammation. The maximum dosage experiment proves that the concentrated solution has the characteristics of higher clinical safety, long-term use and the like. It can be used for preventing and treating xerosis syndrome with clinical symptoms of xerophthalmia, lymphocyte invasion of secretory gland, and inflammation, and is not suitable for recurrence. The formula of the invention has convenient and various taking methods, can be decocted into decoction for taking, and can also be prepared into tablets, pills and powder, thus being convenient for storage and carrying. Can be prepared into tea bags, buccal tablets, effervescent tablets and other dosage forms, and has obvious advantages in the aspect of preventing and treating the sicca syndrome.
3. The prescription of the invention has small dosage, safety and innocuity, is suitable for long-term use of patients with sicca syndrome, and has 15 days of treatment cycle. The invention has better anti-inflammatory effect, can maintain the complete glandular tissue structure, reduce the lymphocyte invasion focus in the gland, reduce the expression level of the autoantibody in the body and simultaneously play a better anti-inflammatory role. Compared with patent 201210296796.0, the prescription of the invention can significantly reduce the lymphocyte infiltration degree in gland with xerosis specificity, and significantly reduce the expression of autoantibody SSA, SSB, ANA and inflammation TNF-alpha, BAFFR.
Drawings
FIG. 1 is a graph showing the effect of the present invention on promoting the crystallization of mouse tear fluid during administration (200X);
FIG. 2 mouse spleen HE staining;
FIG. 3 standard curve for TNF- α in ELISA;
FIG. 4ELISA method SSA protein standard curve;
FIG. 5ELISA method SSB protein standard curve;
FIG. 6ELISA method ANA protein Standard Curve;
FIG. 7ELISA method BAFFR protein standard curve.
Detailed Description
The invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, which is defined in the appended claims, as may be amended by those skilled in the art upon reading the present disclosure, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
2g-30g of selfheal, 2g-30g of desmodium, 2g-30g of spreading hedyotis herb, 2g-30g of chrysanthemum and 2g-30g of honeysuckle, and the five traditional Chinese medicinal materials are taken, extracted by three times of distilled water, filtered, combined with filtrate, and concentrated to 100 mL.
Example 1
2g of selfheal, 2g of desmodium, 2g of spreading hedyotis herb, 2g of chrysanthemum and 2g of honeysuckle, the five traditional Chinese medicinal materials are taken, extracted by distilled water for three times, filtered, the filtrate is combined, and the filtrate is concentrated to 100 mL.
Example 2
7.5g of selfheal, 4g of desmodium, 7.5g of spreading hedyotis herb, 12g of chrysanthemum and 18g of honeysuckle, the five traditional Chinese medicinal materials are taken, extracted by distilled water for three times, filtered, the filtrates are combined, and the filtrate is concentrated to 100 mL.
Example 3
15g of selfheal, 12g of desmodium, 15g of spreading hedyotis herb, 10g of chrysanthemum and 15g of honeysuckle, the five traditional Chinese medicinal materials are taken, extracted by distilled water for three times, filtered, the filtrates are combined, and the filtrate is concentrated to 100 ml.
Example 4
30g of selfheal, 30g of desmodium, 30g of spreading hedyotis herb, 30g of chrysanthemum and 30g of honeysuckle, the five traditional Chinese medicinal materials are taken, extracted by distilled water for three times, filtered, the filtrate is combined, and the filtrate is concentrated to 100 mL.
Example 5
1. Experimental research on effect of traditional Chinese medicine compound extract on relieving dry eye
The specific implementation scheme is as follows: SPF grade Balb/C mice, 48, female, weighing 18-22 g. The mice were randomly divided into 5 groups (n ═ 8) except the normal group, and the sicca syndrome mouse model was replicated using the scopolamine hydrochloride method, with a model replication cycle of 10 days. The mice were divided into a normal control group, a negative control group, a positive drug group (total glucosides of paeony tablets, 0.182g/kg calculated by clinical dose), and groups of examples 1-3 in sequence. Treatment is given from d11, wherein the normal group and the negative control group are perfused with gastric saline, the positive drug group is perfused with gastric white peony root total glycoside liquid medicine, and the test liquid medicine with corresponding concentration is perfused in the groups of examples 1-3. The gavage volume is 1mL/20g body weight, 1 time per day, and the gavage is continuously carried out for 15 days. During this period, tears were removed from the slide glass every 5 days and examined microscopically (200X) for tears crystallization. The weight change and water intake of the mice were measured every 2 days. The test results are shown in table 1, table 2 and fig. 1.
TABLE 1 weight gain in mice during dosing (g, Mean + -SD)
Figure BDA0003052680130000061
Note: (vi) a set of negative models,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。
the results show (Table 1) that the body weight of mice in the negative model group was significantly reduced during the administration period compared with that in the normal group (**P<0.05); mice in the total glucosides of paeony group and the groups of examples 1-3 showed significant weight regain trend from day 3 of administration (d13) compared with the negative model group (see (1))*P<0.05or**P<0.01); compared with the positive control group of total glucosides of paeony, the mice in the examples 1-2 have significantly lower body weight regain than the total glucosides of paeony group (#P<0.05or##P<0.01); however, in example 3, there was no significant difference in the mouse body weight regain (P)>0.05), which shows that the effect of example 3 on the improvement of the body weight of the mice is equivalent to that of the positive control group.
TABLE 2 change in water intake of mice during dosing (mL, Mean + -SD)
Figure BDA0003052680130000071
Note: (vi) a set of negative models,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。
the results show (Table 2) that the consumption of water by the mice in the negative model group was significantly increased during the administration period compared with the normal group (*P<0.05or**P<0.01); compared with the negative model group, the water intake of mice in the total glucosides of paeony group and the groups of examples 1-3 is remarkably reduced after d 13; compared with the total glucosides of paeony positive group, the water intake of example 1 at d13 and d15 is significantly lower than that of the total glucosides of paeony group (45.0 + -4.3 mL and 35.0 + -3.9 mL), 32.4 + -3.8 mL and 29.0 + -3.4 mL, respectively (#P<0.05or##P<0.01). The water intake of the mice in the examples 2 and 3 is not obviously different from that of the white paeony root total glycoside group. It is demonstrated that examples 1-3 had an effect on reducing the water intake of mice comparable to that of the total glucosides of paeony group.
The results show that fern crystal form of model mouse tear crystals is lost (form IV) in irregular punctate form due to the lack of mucin. After 15 days of administration (d25), the tear crystalline forms were improved in both the total glucosides of paeony group and the test group (both form II), except for the model group. Compared with the total glucosides of paeony positive group, the tear crystal forms of the test groups, the examples 2 and the examples 3 have no significant difference with the positive control group.
The test result shows that: the traditional Chinese medicine compound extract has the comprehensive effects of maintaining the weight of a mouse, reducing the water intake of the mouse, repairing the crystalline form of tears and relieving the dry eye disease or is superior to the total glucosides of paeony. The research result can reflect that the traditional Chinese medicine compound extract can prevent and treat dry eye diseases to a certain extent.
2. Experimental study on gland function improvement of traditional Chinese medicine compound extract
The specific implementation scheme is as follows: SPF-grade BALB/c mice 48, female, weighing 18-22 g. The mice were randomly divided into 5 groups (n ═ 8) except the normal group, and the sicca syndrome mouse model was replicated using the scopolamine hydrochloride method, with a model replication cycle of 10 days. The mice were divided into a normal control group, a negative control group, a positive drug group (total glucosides of paeony tablets, 0.182g/kg calculated by clinical dose), and groups of examples 1-3 in sequence. The treatment is started from d11, wherein the normal group and the negative control group are perfused with gastric saline, the positive control group is perfused with gastric white peony root total glycoside liquid medicine, the test liquid medicine with corresponding concentration in the groups of examples 1-3 is perfused with gastric lavage with the gastric lavage volume of 1mL/20g body weight for 1 time/day, and the continuous gavage is carried out for 15 days. After the dosing period was completed, the orbit was bled and the mice were sacrificed. Dissecting, respectively taking submaxillary gland tissue and salivary gland tissue, and placing in 4% neutral formaldehyde solution for 48 h. Then, the slices are sliced after paraffin embedding treatment, and the thickness is 5 mu m; placing the slices in an oven, drying until paraffin is melted, immediately soaking in xylene, and repeating for 2 times; soaking in gradient ethanol (anhydrous, 95%, 90%, 85%, 80%, 75%, 70%) for 10min, and placing in double distilled water; boiling in citrate buffer solution with pH of 6.0 and concentration of 0.01mol/L for 10min for antigen retrieval; washing with running water, washing with distilled water for 3min, and soaking in hematoxylin staining solution for 5 min; washing with flowing water, differentiating with 1% hydrochloric acid ethanol differentiation solution for 5s, and bluing in flowing water for 30 min; soaking in 70% ethanol and 80% ethanol for 3 min; staining with hematoxylin-eosin (HE), soaking in ethanol, and dehydrating for 3 min; and sealing the piece with xylene transparent and neutral resin. Pathological changes such as spleen and the like are observed under a microscope, 5-8 pathological sections are randomly photographed under 100-fold and 200-fold visual fields respectively, and the lymphocyte infiltration degree is evaluated by adopting a Chisholm-Mason histological scoring standard. Grading the grading standard: 0 point, occasional lymphocyte infiltration; 1, dispersing in a small amount of lymphocyte infiltration; 2-moderate infiltration of lymphocytes (not foci) with mild parenchymal lesions; and 3 points are 0-1 lymphocyte infiltration foci occasionally and 5 low-power visual fields. With moderate parenchymal lesions; 2-3 lymphoblastoid infiltrates were easily seen in 4 points, 5 low power fields with severe parenchymal injury. Onset of disease is classified into more than 2 points. The results are shown in tables 3 and 4.
TABLE 3 mouse glandular tissue lymphocyte infiltration score (Mean + -SD)
Figure BDA0003052680130000091
Note: (vi) a set of negative models,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。
the results showed that (Table 3), the degree of lymphocyte infiltration in submaxillary gland tissue of mice in the negative model group was 3.40. + -. 0.55 (compared with that in the normal group)**P<0.01); the degree of lymphocyte infiltration in submaxillary gland tissues was significantly reduced in the total glucosides of paeony group and the test group examples 1-3, as compared with the negative model group (*P<0.05or**P<0.01), 2.40 + -0.55, 2.60 + -0.55, 1.80 + -0.45 and 1.60 + -0.55 respectively; the infiltration scores of the group of example 3 were significantly reduced compared to the total glucosides of paeony group (#P<0.05). It is demonstrated that example 3 inhibits lymphocyte infiltration in submaxillary gland tissue better than the positive control total glucosides of paeony group.
The results show (Table 3) that the degree of lymphocyte infiltration into salivary gland tissue of mice in the negative model group is higher than that in the normal group by 4.10 +/-0.55%**P<0.01); the degree of lymphocyte infiltration in salivary gland tissues was significantly reduced in the total glucosides of paeony group and the test group examples 1 to 3, as compared with the negative model group (**P<0.01), 2.80 + -0.57, 2.50 + -0.50, 1.80 + -0.57 and 1.40 + -0.42, respectively; examples 2-3 groups were assessed for infiltration compared to the total glucosides of paeony groupThe average is remarkably reduced (#P<0.05or##P<0.01). The inhibition effect of the examples 2 and 3 on the lymphocyte infiltration of the salivary gland tissue is better than that of the positive control white paeony root total glycoside group.
The test results show that: the traditional Chinese medicine compound extract has better inhibition effect on the infiltration degree of the lymph cells of submaxillary gland tissues and salivary gland tissues than the positive total glucosides of paeony. The research result reflects that the traditional Chinese medicine compound extract has the functions of protecting the integrity of glandular tissues of secretory glands and maintaining the basic functions of glandular tissues to a certain extent.
3. Test for reducing level of autoantibody by using compound traditional Chinese medicine extract
The specific implementation scheme is as follows: SPF-grade BALB/c mice 48, female, weighing 18-22 g. The mice were randomly divided into 5 groups (n ═ 8) except the normal group, and the sicca syndrome mouse model was replicated using the scopolamine hydrochloride method, with a model replication cycle of 10 days. The mice were divided into a normal control group, a negative control group, a positive drug group (total glucosides of paeony tablets, 0.182g/kg calculated by clinical dose), and groups of examples 1-3 in sequence. The treatment is started from d11, wherein the normal group and the negative control group are perfused with gastric saline, the positive control group is perfused with gastric white peony root total glycoside liquid medicine, the test liquid medicine with corresponding concentration in the groups of examples 1-3 is perfused with gastric lavage with the gastric lavage volume of 1mL/20g body weight for 1 time/day, and the continuous gavage is carried out for 15 days. After the dosing cycle was completed, orbital blood was collected, peripheral blood was collected and upper serum was separated. And detecting the OD value of the light absorption value under the wavelength of 450nm by using an ELISA method. And calculating the expression quantities of the SSA, SSB and ANA proteins in the serum according to the standard curves of the SSA, SSB and ANA proteins in the ELISA kit. The results are shown in Table 5.
TABLE 5 SSA, SSB, ANA protein expression levels (ng/mL, Mean. + -. SD) in peripheral sera of mice
Figure BDA0003052680130000101
Note: (vi) a set of negative models,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。
the results show that the ratio to the normal group isIn comparison, the expression level of SSA, SSB and ANA proteins in peripheral serum of mice in a negative model group is obviously increased (*P<0.05or**P<0.01); compared with a negative model group, the total glucosides of paeony group can obviously inhibit the expression quantity of SSB protein and ANA protein in serum (*P<0.05)(**P<0.01) of 5.1245 + -0.2769 ng/mL and 39.4812 + -6.3827 pg/mL, respectively, but the inhibitory effect on SSA protein was poor at 83.5872 + -6.1035 ng/mL (P)>0.05). Compared with the negative model group, examples 2 to 3 all significantly inhibited the expression levels of SSA, SSB and ANA proteins in peripheral serum of mice (S) ((S))*P<0.05)(**P<0.01), the expression amounts of SSA, SSB and ANA proteins in example 2 are 76.2292 + -7.0896 ng/mL, 4.9715 + -0.1247 ng/mL and 34.4028 + -4.9162 pg/mL, respectively. In example 3, the expression levels of SSA, SSB and ANA proteins were 75.9714 + -6.0628 ng/mL, 4.4812 + -0.1933 ng/mL and 33.1823 + -7.2492 pg/mL, respectively. Compared with the positive control group, the inhibition effect of the example 2 on the expression level of the SSA protein is better than that of the total glucosides of paeony (total glucosides of paeony), (A), (B)#P<0.05), but has no significant difference on the inhibition effect of the expression amount of the SSB and ANA proteins; however, the inhibition effect of example 3 on the expression level of SSA, SSB and ANA proteins is obviously better than that of total glucosides of paeony (A, B and ANA)#P<0.05). Demonstrating that example 3 inhibits autoantibody effects better than the positive control.
And (3) test results: the Chinese medicinal compound extract has better inhibiting effect on the expression quantity of SSA, SSB and ANA proteins in peripheral serum than total glucosides of paeony. The research result reflects that the traditional Chinese medicine compound extract can effectively reduce the expression quantity of the autoantibody to a certain extent.
1. Experimental research on anti-inflammatory effect of traditional Chinese medicine compound extract
The specific implementation scheme is as follows: SPF-grade BALB/c mice 48, female, weighing 18-22 g. The mice were randomly divided into 5 groups (n ═ 8) except the normal group, and the sicca syndrome mouse model was replicated using the scopolamine hydrochloride method, with a model replication cycle of 10 days. The mice were divided into a normal control group, a negative control group, a positive drug group (total glucosides of paeony tablets, 0.182g/kg calculated by clinical dose), and groups of examples 1-3 in sequence. The treatment is started from d11, wherein the normal group and the negative model control group are perfused with gastric normal saline, the radix paeoniae alba total glycoside group perfuses the gastric white paeony root total glycoside liquid medicine, the groups of examples 1-3 are perfused with the tested liquid medicine with corresponding concentration, the perfusion volume is 1mL/20g of body weight, 1 time/day, and the continuous perfusion is carried out for 15 days. After the dosing cycle was completed, orbital blood was collected, peripheral blood was collected and upper serum was separated. And detecting the OD value of the light absorption value under the wavelength of 450nm by using an ELISA method. And calculating the expression levels of the TNF-alpha and BAFFR proteins in the serum according to the standard curves of the TNF-alpha and BAFFR in the ELISA kit. The spleen was removed from the dissected mice, and the spleen coefficients (weight of spleen (mg)/weight of body (g)) were compared. The results are shown in Table 3. And (3) soaking the spleen in a 4% neutral formaldehyde solution for 48 hours to prepare pathological sections, and finishing HE staining. The HE stained pathological section was placed under an inverted microscope and spleen tissue was observed under 100 x and 200 x objective lens in 5 fields at random. The results are shown in table 6, table 7, fig. 2.
TABLE 6 mouse peripheral serum TNF- α, BAFFR protein expression level (Mean + -SD)
Figure BDA0003052680130000111
Figure BDA0003052680130000121
Note: (vi) a set of negative models,*P<0.05or**P<0.01。
the results show (Table 6) that the peripheral serum TNF-alpha expression level of mice in the negative model group is significantly increased compared with that in the normal group (**P<0.01); compared with a negative model group, the total glucosides of paeony can obviously reduce the expression quantity of TNF-alpha in peripheral serum of mice in the total glucosides of paeony group and tested groups of examples 1-3, the expression quantity of the TNF-alpha in the total glucosides of paeony group is 48.6327 +/-4.6231 pg/mL, and the expression quantities of the TNF-alpha in the examples 1-3 are 49.3328 +/-3.2545 pg/mL, 48.5520 +/-4.3418 pg/mL and 44.5130 +/-1.2311 pg/mL respectively. Compared with the positive control group of total glucosides of paeony, the TNF-alpha expression level in the example 3 is obviously reduced, and the statistical difference is shown in (#P<0.05). It is shown that example 3 has an improved effect on the inhibition of TNF-alpha expression over total glucosides of paeony.
BA in peripheral serum of mice in the negative model group, as compared with the normal groupThe FFR expression quantity is obviously increased (**P<0.01); compared with the negative model group, the test group, namely example 1 and example 3, can obviously reduce the BAFFR expression level in the peripheral serum of the mice, namely 9.3760 +/-0.4305 ng/mL and 9.3783 +/-0.3173 ng/mL respectively. However, the total glucosides of paeony positive control group and the control group of the white paeony have no obvious inhibition effect and are 9.9608 +/-1.1633 ng/mL and 9.3918 +/-0.4612 ng/mL respectively. The expression level of BAFFR in example 3 is significantly reduced compared with the positive control group of total glucosides of paeony (statistical difference) ((R))#P<0.05). It is demonstrated that example 3 has an inhibitory effect on BAFFR expression superior to total glucosides of paeony.
TABLE 7 mouse spleen coefficient variation (Mean + -SD)
Figure BDA0003052680130000122
Note: (vi) a set of negative models,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。
the results showed (Table 7) that spleen coefficients were significantly reduced in mice of the negative model group compared to the normal group (*P<0.05) and is 1.3 +/-0.4. Compared with the negative model group, the spleen coefficients of the total glucosides of paeony group and the examples 1 to 3 are significantly higher than those of the model group, namely 2.2 +/-0.8, 2.1 +/-0.6, 2.5 +/-0.9 and 2.8 +/-0.8 respectively. The spleen coefficients of examples 1-3 were not statistically different compared to the total glucosides of paeony positive group. It is demonstrated that examples 1-3 have comparable maintenance of spleen coefficients in mice to total glucosides of paeony.
HE staining results showed (fig. 2) that spleen white marrow of mice in the negative model group was heavily proliferated and germinal center was protruded (grade 3) compared with the normal group (grade 0); compared with the negative model group, the white marrow hyperplasia degree of the white peony root total glycosides group is relieved (grade 2), and the spleen white marrow hyperplasia can be obviously reduced in the tested groups of examples 1-3 (grade 1). Compared with the total glucosides of paeony positive group, the tested groups of examples 1 to 3 have better effect of reducing the splenic leukoplakia hyperplasia than the total glucosides of paeony group.
And (3) test results: the traditional Chinese medicine compound extract has the effects of reducing the expression quantity of TNF-alpha and BAFFR in peripheral serum, reducing spleen myelogenous hyperplasia and improving the spleen coefficient of mice, and is obviously superior to the white paeony root total glycoside positive group. The research result reflects that the traditional Chinese medicine compound extract has good anti-inflammatory effect to a certain extent.
Example 6 examination and implementation-determination of maximum dose of Compound extract of Chinese medicinal herbs
The specific implementation scheme is as follows: SPF-grade BALb/c mice 20, female, weighing 18-22 g. The groups were randomly divided into 2 groups of 10 individuals, each group was a normal control group (normal saline) and an example 4 group (maximum concentration liquid medicine prepared by the compound extract of the Chinese herbal medicine according to example 4). Fasting was 12h (without water deprivation) before the experiment, and gavage was performed in both groups, 1mL/20g body weight, 1 time/day, and 15 days. And recording and observing death conditions, daily weight increase conditions and daily water intake of the mice, observing and recording appearance signs, behavior activities, mental states, appetite, fur, skin color, breathing, excrement and urine and color of the mice, and abnormal secretions of the oral, nasal and ocular genitals and the like, and continuously observing for 15 days. After 15 days, the patient is killed after neck removal, dissected, and visually observed for main organs such as heart, liver, spleen, lung, kidney, gastrointestinal tract and the like, and has obvious pathological morphological changes.
The test results show that the administration dosage is 55 times of the clinical dosage of the adult calculated by the adult weight of 60 kg. After the mice are perfused with the extract with the maximum concentration and the maximum volume, the mice in the group of example 4 have the appearance signs, the behavior activity, the mental state, the appetite, the urine color, the fur, the skin color and the breathing are all normal, and the genitals of the nose, the eye and the oral cavity and the like have no abnormal secretion; the color of the stool particles is dark, the hardness of the particles is moderate, and the constipation phenomenon is avoided. After dissection, the internal organs of both groups of mice were normal. The mice in example 4 and normal groups showed no significant difference in body weight and food intake (P >0.05) as detailed in Table 8, Table 9 and Table 10.
TABLE 8 weight change (g, Mean + -SD) of mice during dosing
Figure BDA0003052680130000131
Figure BDA0003052680130000141
TABLE 9 change in water intake of mice during dosing (mL, Mean + -SD)
Figure BDA0003052680130000142
TABLE 10 mouse abnormalities, deaths, and anatomical changes
Figure BDA0003052680130000143
The basis for selecting total glucosides of paeony as a positive control drug is as follows:
the specific implementation scheme is as follows: SPF grade Balb/C mice 32, female, weight 18-22 g. Except for the normal group, the other mice replicated the sjogren syndrome mouse model by the scopolamine hydrochloride method, and the model replication was completed after 10 days and was randomly grouped (n ═ 8). Mice were divided into normal group, total glucosides of paeony group, hydroxychloroquine group, and example 2 group. The total glucosides of paeony liquid (converted into mouse dose of 0.182g/kg according to clinical dose) is administered to the total glucosides of paeony group except normal group mice; the hydroxychloroquine group is given with hydroxychloroquine sulfate liquid medicine (converted into mouse dose of 0.03g/kg according to clinical dose); the group of example 2 was administered with the respective test solutions. The gavage volume of the mice is 1mL/20g of body weight, 1 time per day, and the gavage is continuously carried out for 15 days. During the period, the weight change and water intake of the mice were measured every 2 days. After the experiment was completed, mouse spleen weight and spleen coefficient were measured. The test results are shown in tables 11, 12 and 13.
Through the investigation of the weight, the water intake and the spleen coefficient of the mice, the intervention effect of the two positive drugs on the SS mice is compared. The results show that the treatment effect of the total glucosides of paeony group is remarkably better than that of the hydroxychloroquine group, and the treatment effect of the group of example 2 is equivalent to that of the hydroxychloroquine group. Therefore, the total glucosides of paeony is preferably used as a positive control drug in the test.
TABLE 11 weight change (g, Mean + -SD) of mice during dosing
Figure BDA0003052680130000144
Figure BDA0003052680130000151
Note: the normal group of the cells is set to v,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。
TABLE 12 change in mouse Water intake during dosing (mL, Mean + -SD)
Figure BDA0003052680130000152
Figure BDA0003052680130000161
Note: the normal group of the cells is set to v,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。
TABLE 13 mouse spleen weight and spleen coefficient variation (Mean + -SD)
Figure BDA0003052680130000162
Note: the normal group of the cells is set to v,*P<0.05or**P<0.01; vs. total glucosides of paeony group,#P<0.05or##P<0.01。

Claims (4)

1. a Chinese medicinal composition is characterized by comprising selfheal, desmodium, oldenlandia diffusa, chrysanthemum and honeysuckle.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising 2g to 30g of selfheal, 2g to 30g of desmodium, 2g to 30g of oldenlandia diffusa, 2g to 30g of chrysanthemum and 2g to 30g of honeysuckle.
3. The preparation method of the traditional Chinese medicine composition according to claim 2 is characterized by comprising the following steps of decocting and concentrating 2g-30g of selfheal, 2g-30g of desmodium, 2g-30g of oldenlandia diffusa, 2g-30g of chrysanthemum and 2g-30g of honeysuckle in water to obtain a finished product.
4. The use of a Chinese medicinal composition according to claim 1 or 2 in the preparation of a medicament for the prevention or treatment of sjogren's syndrome.
CN202110491885.XA 2021-05-06 2021-05-06 Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof Active CN113116973B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110491885.XA CN113116973B (en) 2021-05-06 2021-05-06 Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110491885.XA CN113116973B (en) 2021-05-06 2021-05-06 Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113116973A true CN113116973A (en) 2021-07-16
CN113116973B CN113116973B (en) 2023-01-24

Family

ID=76781537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110491885.XA Active CN113116973B (en) 2021-05-06 2021-05-06 Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113116973B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101264275A (en) * 2008-01-18 2008-09-17 胡三明 Medicated pillow for treating scapulohumeral periarthritis and cervical spondylosis
CN105521008A (en) * 2014-09-28 2016-04-27 张秋云 Children constipation treating mixture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101264275A (en) * 2008-01-18 2008-09-17 胡三明 Medicated pillow for treating scapulohumeral periarthritis and cervical spondylosis
CN105521008A (en) * 2014-09-28 2016-04-27 张秋云 Children constipation treating mixture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘俏敏: "干燥综合征泡什么茶喝", 《HTTPS://WWW.FAMILYDOCTOR.COM.CN/ASK/AUDIO/455374.HTML》 *

Also Published As

Publication number Publication date
CN113116973B (en) 2023-01-24

Similar Documents

Publication Publication Date Title
CN103520572B (en) A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof
CN102631592B (en) Method for preparing traditional Chinese medicine (TCM) for treating pus and blood type colitis
CN103690853B (en) A kind ofly treat Chinese medicine preparation of wet rotten type tinea pedis and preparation method thereof
CN102078473A (en) Traditional Chinese medicine preparation for treating chronic hepatitis b and preparation method thereof
CN104815192A (en) Pharmaceutical composition for treating hypertension and application of pharmaceutical composition
CN102716339B (en) Chinese medicinal composition for treating uremia, and preparation method and application thereof
CN103385993A (en) Chinese medicine preparation for treating gastric ulcer and preparation method thereof
CN104223297B (en) A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof
CN103520552B (en) Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof
CN113116973B (en) Novel traditional Chinese medicine compound for preventing and treating sicca syndrome as well as preparation method and application thereof
CN103505562B (en) For treating the Chinese medicine of keratitis
CN102552767B (en) Traditional Chinese medicine for treating kidney stone, preparation method and administration mode
CN105168662A (en) Traditional Chinese medicine preparation for treating kidney stone and preparation method thereof
CN104983972A (en) Hordeolum treatment drop and preparation method thereof
CN105031595A (en) Traditional Chinese medicine tablet for treating nummular eczema and preparing method thereof
CN1772273A (en) Meridian dredging and lactation promoting medicine or health food composition
CN104189489A (en) Medicament with effect of treating chronic eczema and preparation method thereof
CN109663020A (en) A kind of Yao medicinal composition that treating pruritus and its application
CN104173812A (en) Pharmaceutical composition for treating blood-heat bleeding type acute idiopathic thrombocytopenic purpura and preparation method of pharmaceutical composition
CN103735906A (en) Chinese herb preparation for treating dry bronchiectasis and preparation method thereof
CN103191297B (en) Traditional Chinese medicine composition for treating male infertility and preparation method thereof
CN106039055A (en) Traditional Chinese medicine preparation for treating systemic lupus erythematosus and preparation method
CN104800337A (en) Medicine composition for treating spring conjunctivitis
CN105770229A (en) Medicament for treating cataract and preparation method thereof
CN105943860A (en) Medicine preparation for treating diabetes mellitus and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant